Logo image of NKTX

NKARTA INC (NKTX) Stock News

NASDAQ:NKTX - Nasdaq - US65487U1088 - Common Stock - Currency: USD

1.84  -0.05 (-2.65%)

NKTX Latest News, Press Relases and Analysis

News Image
17 days ago - Zacks Investment Research

Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade

Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News Image
21 days ago - Benzinga

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

Nkarta posts a smaller Q1 loss than expected and maintains strong cash reserves while analysts debate its trial strategy and market position.

News Image
22 days ago - Nkarta, Inc.

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus...

News Image
10 months ago - The Motley Fool

Why Nkarta Stock Is Soaring Today

One analyst is now more bullish about this clinical-stage biotech stock.

Mentions: RJF

News Image
10 months ago - BusinessInsider

NKTX Stock Earnings: Nkarta Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nkarta (NASDAQ:NKTX) just reported results for the second quarter of 2024.Nkart...

News Image
2 months ago - Zacks Investment Research

Nkarta (NKTX) Upgraded to Buy: Here's Why

Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News Image
2 months ago - Nkarta, Inc.

Nkarta to Participate in an April Investor Conference

SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

News Image
10 months ago - InvestorPlace

NKTX Stock Earnings: Nkarta Beats EPS for Q2 2024

NKTX stock results show that Nkarta beat analyst estimates for earnings per share the second quarter of 2024.

News Image
2 months ago - Nkarta, Inc.

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological...

News Image
3 months ago - Nkarta, Inc.

Nkarta to Participate in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

News Image
6 months ago - Nkarta, Inc.

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored...

News Image
6 months ago - Nkarta, Inc.

Nkarta to Participate in an Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

News Image
7 months ago - Nkarta, Inc.

Nkarta to Participate in an Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

News Image
7 months ago - Nkarta, Inc.

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2...

News Image
9 months ago - Nkarta, Inc.

Nkarta to Participate in Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

News Image
10 months ago - Nkarta, Inc.

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis,...

News Image
10 months ago - Nkarta, Inc.

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis,...

News Image
11 months ago - Nkarta, Inc.

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

News Image
a year ago - Nkarta, Inc.

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

News Image
a year ago - InvestorPlace

3 Undervalued Stocks Primed for a 2X Return

Discover compelling investment opportunities with top undervalued stocks for high returns leading in healthcare and software.

Mentions: NOTV RPD